B. Riley Securities has initiated coverage on Nuvation Bio Inc (NUVB) with a Buy rating, effective November 18, 2025. This marks the firm's first assessment of the company, which is focused on developing innovative therapies in oncology.
Nuvation Bio, headquartered in San Francisco, specializes in addressing unmet needs in cancer treatment. The company's pipeline includes taletrectinib, a selective ROS1 inhibitor for non-small cell lung cancer, and safusidenib, an mIDH1 inhibitor. It also develops NUV-1511, a drug-drug conjugate, and NUV-868, a BET inhibitor.
As of the latest data, Nuvation Bio has a market capitalization of $1.6 billion and reported an EPS of -0.64. The upcoming earnings report is scheduled for August 4, 2026, with estimated EPS of -0.12 and revenue of $35.4 million.
The analyst consensus currently stands at 4 Strong Buy, 9 Buy, and 1 Hold, reflecting a positive outlook from 14 analysts. Analyst ratings serve as one of many inputs for investment decisions, highlighting the importance of considering various factors, including company fundamentals and market trends.